Bortezomib-Doxorubicin-Dexamethasone (BDD) for Reversal of Acute Light Chain Induced Renal Failure (ARF) in Multiple Myeloma (MM). Results from a Phase II Study

• Authors: LUDWIG H.; ADAM Z.; HÁJEK Roman; GREIL R.; KEIL F.; ZOJER N.; THALER J.; GISSLINGER H.; LANG A.
• Year of publication: 2008
• Type: Article in Periodical
• Magazine / Source: Blood
• MU Faculty or unit: Faculty of Medicine